Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Ca

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/6/2026

1. MU
2. APTX:CN
3. SPY
4. IQMX
5. EROC
6. MSTR
7. NVDA
8. TSLA
9. MSFT
10. SEER

Go back to Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Ca

Bristol-Myers Squibb Co. (BMY) PT Lowered to $45 at Deutsche Bank

July 23, 2024 6:35 AM EDT

Deutsche Bank analyst James Shin lowered the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $45.00 (from $53.00) while maintaining a Hold rating.

The analyst comments "IQVIA script (TRx) data point to BMY 2Q24 Revs of ~$11.6B to nudge ahead of BBG cons. of ~$11.5B, though non-GAAP EPS of... More